GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stevanato Group SPA (NYSE:STVN) » Definitions » EV-to-EBIT

Stevanato Group SPA (Stevanato Group SPA) EV-to-EBIT : 29.19 (As of May. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Stevanato Group SPA EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Stevanato Group SPA's Enterprise Value is $6,106 Mil. Stevanato Group SPA's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $209 Mil. Therefore, Stevanato Group SPA's EV-to-EBIT for today is 29.19.

The historical rank and industry rank for Stevanato Group SPA's EV-to-EBIT or its related term are showing as below:

STVN' s EV-to-EBIT Range Over the Past 10 Years
Min: 18.98   Med: 33.57   Max: 48.3
Current: 29.19

During the past 6 years, the highest EV-to-EBIT of Stevanato Group SPA was 48.30. The lowest was 18.98. And the median was 33.57.

STVN's EV-to-EBIT is ranked worse than
67.47% of 455 companies
in the Medical Devices & Instruments industry
Industry Median: 20.82 vs STVN: 29.19

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Stevanato Group SPA's Enterprise Value for the quarter that ended in Dec. 2023 was $7,600 Mil. Stevanato Group SPA's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $209 Mil. Stevanato Group SPA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.75%.


Stevanato Group SPA EV-to-EBIT Historical Data

The historical data trend for Stevanato Group SPA's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stevanato Group SPA EV-to-EBIT Chart

Stevanato Group SPA Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - - 29.70 23.24 35.95

Stevanato Group SPA Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.24 34.60 42.76 38.35 35.95

Competitive Comparison of Stevanato Group SPA's EV-to-EBIT

For the Medical Instruments & Supplies subindustry, Stevanato Group SPA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stevanato Group SPA's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stevanato Group SPA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Stevanato Group SPA's EV-to-EBIT falls into.



Stevanato Group SPA EV-to-EBIT Calculation

Stevanato Group SPA's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=6106.020/209.179
=29.19

Stevanato Group SPA's current Enterprise Value is $6,106 Mil.
Stevanato Group SPA's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $209 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stevanato Group SPA  (NYSE:STVN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Stevanato Group SPA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=209.179/7600.48643
=2.75 %

Stevanato Group SPA's Enterprise Value for the quarter that ended in Dec. 2023 was $7,600 Mil.
Stevanato Group SPA's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $209 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stevanato Group SPA EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Stevanato Group SPA's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Stevanato Group SPA (Stevanato Group SPA) Business Description

Traded in Other Exchanges
Address
Via Molinella 17, Piombino Dese, Padua, ITA, 35017
Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato's revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% from South America. It has two segments Biopharmaceutical and Diagnostic Solutions and Engineering.